Emerging pharmacotherapies for neurodevelopmental disorders
about
Treatment of neurodevelopmental disorders in adulthoodPharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.Plexiform neurofibromatosis involving face and oral cavityA 'cure' for Down syndrome: what do parents want?Parents' decisions to screen newborns for FMR1 gene expansions in a pilot research project.Homozygosity mapping in 64 Syrian consanguineous families with non-specific intellectual disability reveals 11 novel loci and high heterogeneityTrisomy 21 and early brain developmentGene expression changes in the MAPK pathway in both Fragile X and Down syndrome human neural progenitor cells.Astrocyte-derived thrombospondins mediate the development of hippocampal presynaptic plasticity in vitroAutism-associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin-neuroligin-mediated transsynaptic signaling.Modeling neurodevelopmental cognitive deficits in tasks with cross-species translational validityA male with cooccurrence of down syndrome and fragile x syndrome.Abnormal Cortical Plasticity in Youth with Autism Spectrum Disorder: A Transcranial Magnetic Stimulation Case-Control Pilot StudyDeveloping new pharmacotherapies for autism.Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions.Pharmacotherapy of conduct disorder: Challenges, options and future directions.Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions.Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia.Pharmacological interventions to improve cognition and adaptive functioning in Down syndrome: Strides to date.Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder.
P2860
Q27000307-C84EEFA8-9ACC-46A6-8045-4083706EBD62Q30422188-8B715A61-626A-4B41-9158-D0228A379342Q30436264-0CC7150F-9C02-4693-B966-3C791F926D9BQ33747513-8174F251-929E-4537-A0F3-02D2942024ADQ35010754-B30FC892-980B-46F8-8AC2-9608D97BE9EDQ35406344-E2320F3A-6B52-4731-A70A-1801E4EBD32CQ35740129-FF157A3B-9365-4A12-B9E0-9FACCAFD4ECDQ36101701-FB8CD4DD-AEFA-4C4C-B4FB-87BBFC54D86FQ36331898-3C1416BA-64AC-4BC0-9FE5-76499EDD64DEQ37117518-62F39841-B0B5-4091-8325-0B4BBD923029Q37126507-D7F232D8-A055-4573-8A45-B052B0396E62Q37191302-76079DCC-4624-4499-BE53-006111E34742Q37281351-61A200C5-B61F-4B75-A881-659ECA5AE190Q38122448-EAC4936A-C33D-4FD7-8E75-D4B40096F603Q38243763-82B26F5B-3EFC-436E-BAFE-A3A844154FE8Q38839950-F0F5C528-A017-44D8-B418-EF8F01D58E18Q42694136-6C6A10DB-80B7-48F2-B66D-F42B093D3FCCQ49789716-B37A2E41-4FEA-4B3E-A970-200D29BBA084Q53081143-534589E8-53C1-4850-9F6A-7F394222CE42Q55180784-930F9F73-831A-410F-B016-28056EB14210
P2860
Emerging pharmacotherapies for neurodevelopmental disorders
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Emerging pharmacotherapies for neurodevelopmental disorders
@ast
Emerging pharmacotherapies for neurodevelopmental disorders
@en
Emerging pharmacotherapies for neurodevelopmental disorders
@nl
type
label
Emerging pharmacotherapies for neurodevelopmental disorders
@ast
Emerging pharmacotherapies for neurodevelopmental disorders
@en
Emerging pharmacotherapies for neurodevelopmental disorders
@nl
prefLabel
Emerging pharmacotherapies for neurodevelopmental disorders
@ast
Emerging pharmacotherapies for neurodevelopmental disorders
@en
Emerging pharmacotherapies for neurodevelopmental disorders
@nl
P2860
P3181
P1476
Emerging pharmacotherapies for neurodevelopmental disorders
@en
P2093
Craig C Garner
Daniel Z Wetmore
P2860
P304
P3181
P356
10.1097/DBP.0B013E3181EE3833
P407
P577
2010-09-01T00:00:00Z